Skip to main content
Erschienen in: Schmerzmedizin 5/2015

09.10.2015 | Zertifizierte Fortbildung

Indikation und Kontraindikation

NSAR in der Schmerztherapie

verfasst von: PD. Dr. med. Michael A. Überall

Erschienen in: Schmerzmedizin | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Nichtsteroidale Antirheumatika gehören weltweit zu den am häufigsten eingesetzten schmerzlindernden Arzneistoffen. Ihrem speziellen Wirkmechanismus und dem damit einhergehenden breiten Spektrum an positiven/erwünschten wie negativen/unerwünschten Wirkungen geschuldet, setzt ihr sinnvoller Einsatz nicht nur ein grundlegendes Wissen um ihre Interaktion mit physiologischen wie pathophysiologischen Prozessen voraus, sondern auch Kenntnisse über Unterschiede der verfügbaren Wirkstoffe und Fertigarzneimittel.
Literatur
1.
Zurück zum Zitat Schwabe U, Paffrath, D. (Hrsg.) Arzneiverordnungs-Report 2014. Aktuelle Daten, Kosten, Trends und Kommentare. Berlin, Heidelberg: Springer-Verlag; 2014.. Schwabe U, Paffrath, D. (Hrsg.) Arzneiverordnungs-Report 2014. Aktuelle Daten, Kosten, Trends und Kommentare. Berlin, Heidelberg: Springer-Verlag; 2014..
3.
4.
Zurück zum Zitat Simmons DL et al. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 2004;56(3):387–437.CrossRefPubMed Simmons DL et al. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 2004;56(3):387–437.CrossRefPubMed
6.
Zurück zum Zitat Massó González EL et al. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum. 2010;62(6): 1592–601.CrossRefPubMed Massó González EL et al. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum. 2010;62(6): 1592–601.CrossRefPubMed
7.
Zurück zum Zitat García Rodríguez LA, Hernández-Díaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology. 2001;12(5):570–6.CrossRefPubMed García Rodríguez LA, Hernández-Díaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology. 2001;12(5):570–6.CrossRefPubMed
8.
Zurück zum Zitat García Rodríguez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology. 2007;132(2):498–506.CrossRefPubMed García Rodríguez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology. 2007;132(2):498–506.CrossRefPubMed
9.
Zurück zum Zitat Lanas A et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal an-ti-inflammatory drugs, aspirin and combinations. Gut. 2006;55(12):1731–8.PubMedCentralCrossRefPubMed Lanas A et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal an-ti-inflammatory drugs, aspirin and combinations. Gut. 2006;55(12):1731–8.PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Stürmer T et al. Determinants of impaired renal function with use of nonsteroidal anti-inflammatory drugs: the importance of half-life and other medications. Am J Med. 2001;111(7):521–7.CrossRefPubMed Stürmer T et al. Determinants of impaired renal function with use of nonsteroidal anti-inflammatory drugs: the importance of half-life and other medications. Am J Med. 2001;111(7):521–7.CrossRefPubMed
11.
Zurück zum Zitat Brune K. Persistence of NSAIDs at effect sites and rapid disappearance from side-effect compartments contributes to tolerability. Curr Med Res Opin. 2007;23(12):2985–95.CrossRefPubMed Brune K. Persistence of NSAIDs at effect sites and rapid disappearance from side-effect compartments contributes to tolerability. Curr Med Res Opin. 2007;23(12):2985–95.CrossRefPubMed
12.
Zurück zum Zitat Brune K et al. Using pharmacokinetic principles to optimize pain therapy. Nat Rev Rheumatol. 2010;6(10):589–98.CrossRefPubMed Brune K et al. Using pharmacokinetic principles to optimize pain therapy. Nat Rev Rheumatol. 2010;6(10):589–98.CrossRefPubMed
13.
Zurück zum Zitat García Rodríguez LA et al. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol. 2008;52(20):1628–361628-36.CrossRefPubMed García Rodríguez LA et al. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol. 2008;52(20):1628–361628-36.CrossRefPubMed
14.
Zurück zum Zitat Castellsague J et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012;35(12):1127–46.PubMedCentralCrossRefPubMed Castellsague J et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012;35(12):1127–46.PubMedCentralCrossRefPubMed
15.
Zurück zum Zitat McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8(9):e1001098.PubMedCentralCrossRefPubMed McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8(9):e1001098.PubMedCentralCrossRefPubMed
16.
Zurück zum Zitat Huerta C et al. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis. 2005;45(3):531–9.CrossRefPubMed Huerta C et al. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis. 2005;45(3):531–9.CrossRefPubMed
17.
Zurück zum Zitat Lewis SC et al. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointesti-nal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol. 2002;54(3):320–6.PubMedCentralCrossRefPubMed Lewis SC et al. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointesti-nal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol. 2002;54(3):320–6.PubMedCentralCrossRefPubMed
18.
Zurück zum Zitat Rostom A et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol. 2007;5(7):818–28.CrossRefPubMed Rostom A et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol. 2007;5(7):818–28.CrossRefPubMed
19.
Zurück zum Zitat Solomon DH et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004;109(17):2068–73.CrossRefPubMed Solomon DH et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004;109(17):2068–73.CrossRefPubMed
20.
Zurück zum Zitat Solomon SD et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008;117(16):2104–13PubMedCentralCrossRefPubMed Solomon SD et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008;117(16):2104–13PubMedCentralCrossRefPubMed
21.
Zurück zum Zitat Olsen AM et al. Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients-a nationwide study. PLoS One. 2013;8(1):e54309.CrossRefPubMed Olsen AM et al. Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients-a nationwide study. PLoS One. 2013;8(1):e54309.CrossRefPubMed
22.
Zurück zum Zitat Theiler R. Schmerztherapie bei Arthrose - wie weiter mit Coxiben und konventionellen NSAR? Der Informierte Arzt. 2012;2(2):18–21. Theiler R. Schmerztherapie bei Arthrose - wie weiter mit Coxiben und konventionellen NSAR? Der Informierte Arzt. 2012;2(2):18–21.
23.
Zurück zum Zitat Hernández-Díaz S, Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160(14):2093–9.CrossRefPubMed Hernández-Díaz S, Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160(14):2093–9.CrossRefPubMed
24.
Zurück zum Zitat Lanas A et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol. 2005;100(8):1685–93.CrossRefPubMed Lanas A et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol. 2005;100(8):1685–93.CrossRefPubMed
25.
Zurück zum Zitat Lanas A et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol. 2009;104(7):1633–41.CrossRefPubMed Lanas A et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol. 2009;104(7):1633–41.CrossRefPubMed
26.
Zurück zum Zitat Chan FK et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010;376(9736):173–9.CrossRefPubMed Chan FK et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010;376(9736):173–9.CrossRefPubMed
27.
Zurück zum Zitat Kellner HL et al. Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial. Curr Med Res Opin. 2012;28(9):1537–45.CrossRefPubMed Kellner HL et al. Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial. Curr Med Res Opin. 2012;28(9):1537–45.CrossRefPubMed
28.
Zurück zum Zitat Laine L et al. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2006;24(5):751–67.CrossRefPubMed Laine L et al. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2006;24(5):751–67.CrossRefPubMed
29.
Zurück zum Zitat Spies CM et al. How to mechanistically explain the CONDOR study data. Med Hypotheses. 2015;84(1):14–9.CrossRefPubMed Spies CM et al. How to mechanistically explain the CONDOR study data. Med Hypotheses. 2015;84(1):14–9.CrossRefPubMed
30.
Zurück zum Zitat Salvo F et al. Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials. Clin Pharmacol Ther. 2011;89(6):855–66.CrossRefPubMed Salvo F et al. Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials. Clin Pharmacol Ther. 2011;89(6):855–66.CrossRefPubMed
31.
Zurück zum Zitat Cannon CP et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006;368(9549):1771–81.CrossRefPubMed Cannon CP et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006;368(9549):1771–81.CrossRefPubMed
32.
Zurück zum Zitat Laine L et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2007;369(9560):465–73.CrossRefPubMed Laine L et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2007;369(9560):465–73.CrossRefPubMed
33.
Zurück zum Zitat Combe B et al. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology (Oxford). 2009;48(4):425–32.CrossRef Combe B et al. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology (Oxford). 2009;48(4):425–32.CrossRef
34.
Zurück zum Zitat Keil U et al. Risikoabschätzung tödlicher Herz-Kreislauf-Erkrankungen: Die neuen SCORE-Deutschland-Tabellen für die Primärprävention. Dtsch Arztebl 2005;102(25): A-1808/B-1526/C-1441. Keil U et al. Risikoabschätzung tödlicher Herz-Kreislauf-Erkrankungen: Die neuen SCORE-Deutschland-Tabellen für die Primärprävention. Dtsch Arztebl 2005;102(25): A-1808/B-1526/C-1441.
35.
Zurück zum Zitat Feldman H et al. Parenteral ketorolac: the risk for acute renal failure. Ann Intern Med. 1997;126(3):193–9.CrossRefPubMed Feldman H et al. Parenteral ketorolac: the risk for acute renal failure. Ann Intern Med. 1997;126(3):193–9.CrossRefPubMed
36.
Zurück zum Zitat Fitzgerald, GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345(6):433–42.CrossRefPubMed Fitzgerald, GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345(6):433–42.CrossRefPubMed
37.
Zurück zum Zitat Baigent C, Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal. Arthritis Rheum. 2003;48(1):12–20.CrossRefPubMed Baigent C, Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal. Arthritis Rheum. 2003;48(1):12–20.CrossRefPubMed
38.
Zurück zum Zitat Antonucci R et al. Use of non-steroidal anti-inflammatory drugs in pregnancy: impact on the fetus and newborn. Curr Drug Metab. 2012;13(4):474–90.CrossRefPubMed Antonucci R et al. Use of non-steroidal anti-inflammatory drugs in pregnancy: impact on the fetus and newborn. Curr Drug Metab. 2012;13(4):474–90.CrossRefPubMed
40.
Zurück zum Zitat Massey T et al. Topical NSAIDs for acute pain in adults. Cochrane Database Syst Rev. 2010;6:CD007402.PubMed Massey T et al. Topical NSAIDs for acute pain in adults. Cochrane Database Syst Rev. 2010;6:CD007402.PubMed
41.
Zurück zum Zitat Derry S et al. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2012;9:CD007400).PubMedCentralPubMed Derry S et al. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2012;9:CD007400).PubMedCentralPubMed
Metadaten
Titel
Indikation und Kontraindikation
NSAR in der Schmerztherapie
verfasst von
PD. Dr. med. Michael A. Überall
Publikationsdatum
09.10.2015
Verlag
Urban & Vogel
Erschienen in
Schmerzmedizin / Ausgabe 5/2015
Print ISSN: 2194-2536
Elektronische ISSN: 2364-1010
DOI
https://doi.org/10.1007/s00940-015-0108-1

Weitere Artikel der Ausgabe 5/2015

Schmerzmedizin 5/2015 Zur Ausgabe

DGS_Deutsche Gesellschaft für Schmerzmedizin e. V.

Kriterienkatalog für schmerzmedizinische Einrichtungen

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.